Pfizer reports positive data from high-dose Toviaz trial

Pfizer has posted new clinical trial data showing the efficacy of its overactive bladder therapy Toviaz when used in a higher dosage strength.

In the new phase IV study, it was demonstrated that a once-daily 8 mg version of the treatment reduced urge urinary incontinence in patients more effectively than a 4 mg dose, with both options delivering benefits compared to placebo.

The safety and tolerability profile of both Toviaz doses in this study were consistent with previous studies, with the overall conclusion of the study suggesting that the higher dose can be suitable for patients who require additional efficacy beyond the standard version.

Dr Steven Romano, senior vice-president and medicines development group head for Pfizer's primary care business unit, said: "We are aware of no other approved overactive bladder medication that has demonstrated statistically superior efficacy of its higher dose versus lower dose in reducing urge urinary incontinence."

This comes after the company also recently reported positive data from phase IV trials of its depression therapy Pristiq and smoking cessation aid Champix.